Clinical trials: Chemoradiation
Cancer, Head and Neck Cancer
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first…
- Conditions
- Cancer, Head and Neck Cancer, Oncology, Squamous Cell Carcinoma
- Trial name
- NCT00547157
- Testing
- Panitumumab, Cisplatin
- Volunteers
- 152 people
- Sponsor
- Amgen
Esophagitis
Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
GTI-4419-203 will be an open-label, multi-center study to evaluate GC4419 (avasopasem manganese) administered intravenous (IV) for the reduction of radiation induced esophagitis in subjects receiving chemoradiotherapy for…
- Trial name
- NCT04225026
- Testing
- GC4419 (avasopasem manganese)
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Galera Therapeutics, Inc.
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab…
- Trial name
- PACIFIC-9 (NCT05221840)
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 202 sites in United States, Australia and 18 more
- Volunteers
- 1,051 people
- Sponsor
- AstraZeneca
Lung Cancer
Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy
Patients (pts) with stage IIIA/IIIB NSCLC received NVBiv 25 mg/m² + CDDP 80 mg/m² on D1 and NVBo 60 mg/m² on D8 every 3 weeks (q3w) for 2 cycles as induction.
- Trial name
- NCT01839032
- Testing
- Vinorelbine cisplatin radiotherapy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Pierre Fabre Medicament
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
The working hypothesis is that oral rigosertib treatment when added to platinum-based Chemoradiotherapy (CRT) will improve progression-free survival for first-line patients with intermediate- or high-risk human papillomavirus…
- Trial name
- NCT02107235
- Testing
- oral rigosertib, cisplatin, Radiotherapy
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Traws Pharma, Inc.
Pancreatic Cancer
Immunotherapy Study for Surgically Resected Pancreatic Cancer
The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in…
- Trial name
- NCT01072981
- Testing
- HyperAcute-Pancreas Immunotherapy, Gemcitabine, 5FU Chemoradiation
- Where
- 75 sites in United States
- Volunteers
- 722 people
- Sponsor
- NewLink Genetics Corporation
Head and Neck Cancer
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
- Trial name
- IRESSA&H&N (NCT00681967)
- Testing
- Gefitinib
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
NSCLC, Stage III
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer…
- Trial name
- NCT05386888
- Testing
- GFH018, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Small Cell Lung Cancer
INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
This is a clinical study on the use of iNK cells for the treatment of small cell lung cancer.
- Trial name
- iNK-SCLC (NCT06747832)
- Testing
- iNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangzhou Ruixin Biotechnological Co., LTD
Resectable Esophageal Squamous Cell Carcinoma
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
- Trial name
- RATIONALE-213 (NCT04974047)
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 70 people
- Sponsor
- BeiGene
Locally Advanced Nasopharyngeal Carcinoma
Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma
RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study of mono famitinib has shown that the drug's toxicity is manageable.
- Trial name
- FMTN-I-LNPC (NCT01462474)
- Testing
- Famitinib, Cisplatin, radiation（IMRT）
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Carcinoma, Non-Small-Cell Lung
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy
To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in…
- Trial name
- NCT03643484
- Where
- 37 sites in Japan
- Volunteers
- 634 people
- Sponsor
- AstraZeneca
Oral Mucositis
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy.
- Trial name
- NCT00289003
- Testing
- Soluble beta-1,3/1,6-glucan
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Biotec Pharmacon ASA
Newly Diagnosed Glioblastoma
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
This is a single-arm, open-label phase II clinical trial in which approximately 55 patients with newly diagnosed glioblastoma (GBM) will be enrolled with the intent to receive an autologous dendritic cell vaccine consisting of…
- Trial name
- NCT03400917
- Testing
- AV-GBM-1
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Aivita Biomedical, Inc.
Head and Neck Cancer, Squamous Cell Carcinoma
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed.
- Trial name
- NCT00500760
- Testing
- Cisplatin, Standard Fractionation Radiotherapy, Panitumumab
- Volunteers
- 153 people
- Sponsor
- Amgen
Neoplasms, Head and Neck
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
- Trial name
- JADE (NCT06256588)
- Testing
- Dostarlimab
- Where
- 277 sites in United States, Argentina and 29 more
- Volunteers
- 864 people
- Sponsor
- GlaxoSmithKline